Canada markets closed
  • S&P/TSX

    20,206.41
    +106.60 (+0.53%)
     
  • S&P 500

    4,008.01
    -15.88 (-0.39%)
     
  • DOW

    32,223.42
    +26.76 (+0.08%)
     
  • CAD/USD

    0.7790
    +0.0005 (+0.07%)
     
  • CRUDE OIL

    113.87
    -0.33 (-0.29%)
     
  • BTC-CAD

    38,502.52
    -1,595.11 (-3.98%)
     
  • CMC Crypto 200

    670.71
    +428.03 (+176.38%)
     
  • GOLD FUTURES

    1,826.30
    +12.30 (+0.68%)
     
  • RUSSELL 2000

    1,783.43
    -9.24 (-0.52%)
     
  • 10-Yr Bond

    2.8770
    -0.0580 (-1.98%)
     
  • NASDAQ futures

    12,254.25
    +9.50 (+0.08%)
     
  • VOLATILITY

    27.47
    -1.40 (-4.85%)
     
  • FTSE

    7,464.80
    +46.65 (+0.63%)
     
  • NIKKEI 225

    26,539.94
    -7.11 (-0.03%)
     
  • CAD/EUR

    0.7453
    -0.0001 (-0.01%)
     

Merck Snags Yet Another Indication for This Drug Combo

·4 min read
Merck Snags Yet Another Indication for This Drug Combo
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

The company's blockbuster cancer drug Keytruda was approved in Japan to treat patients with certain types of endometrial cancer.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting